Cochrane · systematic review · CD008927
Antibody induction therapy for lung transplant recipients
Penninga, L, Møller, CH, Penninga, EI, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 15 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
T‐cell antibody induction compared with no antibody induction for lung transplant recipients
Population: lung transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality T‐cell antibody induction vs no antibody induction | RR 0.99 [0.69, 1.41] | 3 studies · 140 participants | Moderate Downgraded: risk of bias |
Acute rejection grade II or higher T‐cell antibody induction vs no antibody induction | RR 0.66 [0.43, 1.02] | 3 studies · 140 participants | Moderate Downgraded: risk of bias |
Infection T‐cell antibody induction vs no antibody induction | RR 1.4 [0.97, 2.01] | 2 studies · 104 participants | Moderate Downgraded: risk of bias |
Bronchiolitis obliterans syndrome T‐cell antibody induction vs no antibody induction | RR 0.77 [0.55, 1.09] | 3 studies · 140 participants | Moderate Downgraded: risk of bias |
Polyclonal T‐cell antibody compared with no antibody induction for lung transplant recipients
Population: lung transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Polyclonal T‐cell antibody vs no antibody induction | RR 1.02 [0.71, 1.47] | 3 studies · 125 participants | Moderate Downgraded: risk of bias |
Acute rejection grade II or higher Polyclonal T‐cell antibody vs no antibody induction | RR 0.68 [0.44, 1.04] | 3 studies · 125 participants | Moderate Downgraded: risk of bias |
Infection Polyclonal T‐cell antibody vs no antibody induction | RR 1.4 [0.97, 2.01] | 2 studies · 104 participants | Moderate Downgraded: risk of bias |
Bronchiolitis obliterans syndrome Polyclonal T‐cell antibody vs no antibody induction | RR 0.81 [0.57, 1.16] | 3 studies · 125 participants | Moderate Downgraded: risk of bias |
IL‐2 receptor antagonist induction compared with no antibody induction for lung transplant recipients
Population: lung transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality IL‐2 receptor antagonist induction vs no antibody induction | RR 0.67 [0.22, 2.07] | 1 study · 25 participants | Moderate Downgraded: risk of bias |
Acute rejection IL‐2 receptor antagonist induction vs no antibody induction | RR 1.07 [0.49, 2.33] | 1 study · 25 participants | Moderate Downgraded: risk of bias |
Bronchiolitis obliterans syndrome IL‐2 receptor antagonist induction vs no antibody induction | RR 0.33 [0.07, 1.49] | 1 study · 25 participants | Moderate Downgraded: risk of bias |
Polyclonal T‐cell antibody induction compared with interleukin‐2 receptor antagonist induction for lung transplant recipients
Population: lung transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Polyclonal T‐cell antibody induction vs interleukin‐2 receptor antagonist induction | RR 1.41 [0.55, 3.64] | 3 studies · 100 participants | Moderate Downgraded: risk of bias |
Acute rejection Polyclonal T‐cell antibody induction vs interleukin‐2 receptor antagonist induction | RR 1.33 [0.93, 1.92] | 2 studies · 76 participants | Moderate Downgraded: risk of bias |
Infection Polyclonal T‐cell antibody induction vs interleukin‐2 receptor antagonist induction | RR 0.91 [0.71, 1.16] | 1 study · 50 participants | Moderate Downgraded: risk of bias |
Bronchiolitis obliterans syndrome Polyclonal T‐cell antibody induction vs interleukin‐2 receptor antagonist induction | RR 1.66 [0.42, 6.53] | 2 studies · 76 participants | Moderate Downgraded: risk of bias |